Truist Financial Maintains Vericel(VCEL.US) With Buy Rating
Truist Securities Cuts Price Target on Vericel to $61 From $67, Keeps Buy Rating
A Quick Look at Today's Ratings for Vericel(VCEL.US), With a Forecast Between $60 to $72
Analysts Offer Insights on Healthcare Companies: Vericel (VCEL), Radnet (RDNT) and Universal Health (UHS)
Truist Financial Remains a Buy on Vericel (VCEL)
Vericel Analyst Ratings
Vericel's Growth Potential: Expanding MACI Franchise and Burn Care Innovations Drive Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: Vericel (VCEL), Astria Therapeutics (ATXS)
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $67
Vericel Is Maintained at Buy by Canaccord Genuity
Vericel Analyst Ratings
H.C. Wainwright Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $60
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $64
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $72
TD Cowen Remains a Buy on Vericel (VCEL)
Vericel Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Vericel Analyst Ratings
Citi Initiates Vericel(VCEL.US) With Buy Rating, Announces Target Price $60
Vericel's Strong Growth Prospects and MACI Product Drive Buy Rating Amid Positive Revenue Trajectory and Future Expansion Plans
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $72